PF-Atlas › Clinical Trials › NCT05041426

Letermovir for CMV Prevention After Lung Transplantation

Letermovir · Phase 2

Registry ID

NCT05041426

Phase

Phase 2

Status

Completed

Drug / intervention

Letermovir

Sponsor

Fernanda P Silveira, MD, MS

Start

2021-12-06

Enrollment

Locations

About this trial

This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).

View NCT05041426 on ClinicalTrials.gov →

Explore related

All Letermovir trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05041426 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.